Clinical Trial Update: Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of Cycloset added to GLP-1 analogue therapy on glycemic control in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CYCLOSET (BROMOCRIPTINE MESYLATE)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED | Results posted: 2019-06-21